Hologic, Inc. is a Massachusetts-based company that focuses on women’s health, developing diagnostics products, medical imaging systems, and surgical products. With a market cap of $14.4 billion, it operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Analysts expect Hologic to report an adjusted EPS of $1.05 for fiscal Q3 2025, a slight decrease from the year-ago quarter. For fiscal 2025, the company is projected to have an adjusted EPS of $4.19, showing a 2.7% year-over-year increase.

HOLX stock has declined 16.8% in the past 52 weeks, underperforming the S&P 500 Index and the Health Care Select Sector SPDR Fund. Following its Q2 2025 results, the stock dropped 1.6% due to a revenue decline and lower sales of mammography equipment.

Analysts have a “Moderate Buy” rating on Hologic stock, with a mean price target of $68.67, suggesting a 6.3% potential upside. Six analysts recommend “Strong Buy,” one suggests a “Moderate Buy,” and 12 advise “Hold” on the stock.

Read more at Yahoo Finance: What to Expect From Hologic’s Q3 2025 Earnings Report